# Analytical Pharmacology

> **NIH NIH P30** · JOHNS HOPKINS UNIVERSITY · 2022 · $216,242

## Abstract

PROJECT SUMMARY/ABSTRACT
 The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Analytical Pharmacology Shared Resource
(APSR) has offered state-of-the-art and cost-effective analytical chemistry and clinical pharmacology services
to Members continuously since its inception in 1985. The APSR provides instrumentation and facilities in a
1,750 ft2 laboratory on the first floor of the SKCCC Bunting-Blaustein Cancer Research Building. The specific
aims of APSR are to: 1) provide expertise in clinical trial and preclinical study design, with a focus on critical
pharmacological endpoints; 2) provide state-of-the-art, Good Laboratory Practice-quality, cost-effective
services to quantitate anticancer drugs and metabolites or biomarkers in biological fluids; and 3) provide
exposure-response analysis and interpretation, with the long-term vision of providing decision tools for drug
development in both the preclinical and clinical settings. The APSR houses four ultra-performance liquid
chromatography instruments with one UV/Vis detector, three triple-stage quadruple mass spectrometers, one
QTrap system with ion trap capabilities for more intricate drug metabolism studies, and one ion mobility
spectrometer. The APSR analyzes ~3,600 samples/year, develops ~15 new methods involving ~30 analytes
per year and serves 29 faculty members across six of the CCSG Programs (plus nonprogrammatically
aligned), with the majority of the users having peer-reviewed funding. The APSR remains a critical component
across the translational spectrum, providing services in analytical method development (two manuscripts), drug
discovery (three manuscripts), preclinical studies (16 manuscripts), clinical trials (18 manuscripts), exposure-
response analyses (five manuscripts) and three other manuscripts. The APSR has participated in the
submission of 57 cancer-focused grants over five years (across all CCSG Programs); played a major role in
the successful applications for the Johns Hopkins Early Therapeutics Clinical Trials Network (UM1), AIDS
Malignancy Consortium (UM1) and Chesapeake-Ohio Pharmacokinetics Core for the ETCTN (U24); and
serves as a second laboratory for the Adult Brain Tumor Consortium (UM1). The requested CCSG funding will
support personnel who provide consultative services related to assay development, protocol design and data
interpretation, and ensure that instrumentation is suitably maintained and utilized efficiently.
SKCCC Managed Shared Resource
Reporting Period: January 1, 2020 to December 31, 2020

## Key facts

- **NIH application ID:** 10409366
- **Project number:** 2P30CA006973-59
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** MICHELLE A RUDEK
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $216,242
- **Award type:** 2
- **Project period:** 1997-05-07 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10409366

## Citation

> US National Institutes of Health, RePORTER application 10409366, Analytical Pharmacology (2P30CA006973-59). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10409366. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*